Survodutide

Survodutide is a synthetic, lipidated peptide engineered as a balanced dual agonist of the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). Like semaglutide, it carries a fatty-acid chain that promotes albumin binding and resistance to enzymatic degradation, supporting once-weekly subcutaneous dosing. The GLP-1R arm drives glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying and central appetite reduction, while the added glucagon-receptor arm is proposed to raise energy expenditure and enhance hepatic lipid metabolism. This complementary dual action is the rationale for studying it in both obesity and metabolic liver disease, where reducing hepatic fat is a primary goal.

Survodutide is investigational and not approved in any jurisdiction; evidence comes from phase 2 trials. A dose-finding phase 2 obesity trial (le Roux et al., Lancet Diabetes Endocrinol 2024) reported mean body-weight reductions up to roughly 19% at 46 weeks with the highest dose versus placebo. A separate phase 2 trial in biopsy-confirmed MASH with fibrosis (Sanyal et al., NEJM 2024) found histologic improvement of MASH without worsening of fibrosis in 47-62% of treated participants versus 14% on placebo. Phase 3 programs are underway, so efficacy and long-term safety remain unconfirmed.

Educational overview only — no dosing instructions in the public hub.

The most common adverse effects reported in trials are gastrointestinal — nausea, vomiting and diarrhea — generally dose-dependent and most pronounced during dose escalation. Increases in heart rate have been observed, consistent with the incretin/glucagon class. Because survodutide is investigational, its long-term safety, cardiovascular profile and rare-event risks are not established outside monitored clinical trials. Non-trial, 'research use only' material adds unquantified hazards: uncertain identity, dosing accuracy and purity, and no clinical supervision to manage side effects or contraindications.

Survodutide is an experimental biologic not available as an approved medicine, so any product sold to consumers falls outside pharmaceutical quality assurance. At minimum, a third-party certificate of analysis documenting identity, purity and quantification (e.g., HPLC plus mass spectrometry) is the floor for verification — but even a clean CoA cannot substitute for the safety and efficacy data that only completed trials and regulatory review provide.

Investigational — in phase 2/3 clinical trials and not approved by the FDA, EMA or any other regulator for human use. It is not a licensed medicine; any sale for human consumption sits outside the approved framework and lacks quality assurance and medical supervision. Promising but unproven.